Advanced lipid-lowering therapies are reshaping the hyperlipidemia drug market as clinicians treat high-risk patients who may not achieve adequate cholesterol reduction with conventional oral therapies alone. PCSK9 inhibitors, small-interfering RNA treatments, and other non-statin medicines are creating new therapeutic pathways.marketresearchfuture PCSK9 inhibitors are the fastest-growing drug...